Who we are

Synergus RWE is dedicated to developing and executing RWE strategies for decision makers in Europe.

Consulting

Synergus provides support with development of all common types of value documentation (value summary, core value dossier and business case) and apps for value communication

more

Real World Data Sources

We have developed a proprietary database with RWD sources and methods to identify and assess where you can find the right data to answer the question of interest. We have more than 400 data-sets in our data-base.

my-RWE : The disease specific insights

We have developed a framework of how to develop a disease specific framework for the RWE research to optimize transparent outcomes that will be accepted by decision makers.

 

RWE analysis

We help you execute the RWE analysis through our experts.

 

 

 

Securing Market Access

With Synergus Analytics we have started a journey to create insight in different data sets relating to healthcare. In our process we are combining manual analysis of data with a process of learning how to use smart technical solutions to extract data

more

Market Access

Our business is to help you find the most optimal way to establish the desired market uptake in your countries of target. In this process we can provide services throughout the life cycle, starting with the development of the market access strategy to the execution of either health economic evidence or changing the reimbursement system

Evidence strategy

Analyzing evidence requirements for technology and contributing to evidence generation strategy. Strategy includes perspective of key stakeholders: reimbursement / HTA authorities, clinical societies, medical community and competitors

Systematic reviews

Developing and publishing results of state-of-art systematic literature reviews and meta-analysis.

Reimbursement country overviews

Comprehensive overview of reimbursement systems in European countries in the report format. 

read more

 

 

Blog

31
Aug 2018

The European Medicines Agency (EMA) recently released a report into the differences of medications and medicines on children and infants.

27
Aug 2018

In a recent tweet from the International Society for Pharmacoepidemiology (@ICPE) it was stated from a company that they had the only validated real-world evidence platform that enables reproducibl

22
Aug 2018

Norway not only has a rich source of oil but has a rich supply of real world data sources (RWDs), especially when in concerns the central nervous system!

News

12
Oct 2018

We are happy to announce an extension of our services to cover the Middle East. 

tags:
08
Oct 2017

Don't miss to stop by our booth at Ispor in Glasgow.

We have booth 108.

tags:
09
Aug 2017

Here is a the result from our first AI based newsletter regarding rheumatoid arthritis.

Get in Contact

Secure your market entry

Contact us Find us